NuVasive

OverviewSuggest Edit

NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. Its principal product offering is based on its Maximum Access Surgery, or MAS platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. 
TypePublic
Founded1997
HQSan Diego, USMap
Websitenuvasive.com
Employee Ratings3.7More
View Jobs (75)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)2,800(+8%)
Job Openings75
Revenue (FY, 2019)$1.2 B(+7%)
Share Price (Jul 2020)$53.5 (-1%)
Cybersecurity ratingBMore

Key People/Management at NuVasive

Matt Harbaugh

Matt Harbaugh

Executive Vice President and Chief Financial Officer
Dale Wolf

Dale Wolf

Senior Vice President, Global Operations
Lucas Vitale

Lucas Vitale

Chief Human Resources Officer
Nathaniel Sisitsky

Nathaniel Sisitsky

Senior Vice President, General Counsel and Corporate Secretary
Aviva McPherron

Aviva McPherron

Vice President, Information Technology
Suzanne Hatcher

Suzanne Hatcher

Vice President, Internal and External Affairs
Show more

NuVasive Office Locations

NuVasive has offices in San Diego, Aliso Viejo, Columbia, Fairborn and in 14 other locations
San Diego, US (HQ)
7475 Lusk Blvd
Aliso Viejo, US
101 Enterprise #100
Columbia, US
10420 Little Patuxent Pkwy #250
Fairborn, US
1 Herald Square
Memphis, US
4670 E Shelby Dr #101
Kew, AU
620 High St
Show all (18)

NuVasive Financials and Metrics

NuVasive Revenue

Embed Graph
View revenue for all periods
NuVasive's revenue was reported to be $1.17 b in FY, 2019
USD

Revenue (Q1, 2020)

259.9m

Gross profit (Q1, 2020)

188.0m

Gross profit margin (Q1, 2020), %

72.3%

Net income (Q1, 2020)

5.3m

Market capitalization (9-Jul-2020)

2.7b

Closing stock price (9-Jul-2020)

53.5

Cash (31-Mar-2020)

512.0m

EV

3.3b
NuVasive's current market capitalization is $2.7 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014Y, 2014Y, 2015FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

478.2m540.5m620.3m685.2m762.4m762.4m811.1m811.1m962.1m1.0b1.1b1.2b

Revenue growth, %

11%6%19%

Cost of goods sold

85.1m112.1m153.4m180.5m182.4m182.4m194.5m194.5m240.1m269.0m311.2m312.4m

Gross profit

393.1m428.4m466.8m504.7m580.1m580.1m616.6m616.6m722.0m760.5m790.6m855.7m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

119.6m120.3m124.5m133.0m132.9m151.7m154.4m148.4m159.5m165.7m169.2m177.5m190.7m189.9m192.4m202.9m200.5m215.1m236.2m239.6m249.9m260.6m247.4m260.5m281.6m271.3m274.8m292.1m290.8m259.9m

Cost of goods sold

21.0m21.6m23.5m25.5m26.0m36.9m36.5m37.7m39.1m48.7m43.3m43.3m44.8m47.7m45.7m48.4m49.2m54.2m59.7m59.2m61.6m66.4m65.6m73.8m77.1m74.2m74.5m77.6m77.0m71.9m

Gross profit

98.6m98.7m100.9m107.5m106.9m114.8m117.9m110.6m120.4m117.0m125.9m134.2m145.8m142.2m146.7m154.5m151.4m160.9m176.5m180.5m188.3m194.2m181.8m186.7m204.5m197.1m200.3m214.5m213.8m188.0m

Gross profit Margin, %

82%82%81%81%80%76%76%75%75%71%74%76%76%75%76%76%75%75%75%75%75%75%73%72%73%73%73%73%74%72%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

92.6m163.5m123.3m102.8m142.4m192.3m153.6m72.8m117.8m213.0m

Accounts Receivable

76.6m88.4m89.0m104.8m119.0m127.6m199.0m196.5m211.5m

Prepaid Expenses

19.9m8.5m10.9m21.6m8.8m18.8m13.7m16.9m

Inventories

107.6m119.3m126.3m136.9m154.6m168.1m208.2m247.2m273.2m312.4m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

67.5m70.6m134.1m505.1m220.9m270.2m121.2m107.7m78.5m58.9m100.6m110.8m106.5m130.7m88.5m78.6m141.3m270.1m263.1m203.8m134.0m130.9m62.2m73.7m70.1m75.1m93.4m128.4m163.4m512.0m

Accounts Receivable

68.2m71.6m76.0m80.5m78.6m85.6m85.7m78.1m90.4m96.3m96.2m106.3m112.6m108.4m111.5m116.8m115.6m126.1m141.9m143.8m172.1m190.2m187.2m188.1m199.9m191.6m194.4m208.0m203.6m186.8m

Prepaid Expenses

4.7m5.1m9.2m8.1m7.3m9.1m9.0m10.1m11.3m11.8m10.2m9.0m8.4m7.3m7.8m8.1m9.6m12.9m12.3m9.2m21.1m23.6m23.4m13.6m14.6m14.6m17.3m

Inventories

93.1m98.8m114.4m118.0m122.6m122.0m128.6m133.0m129.6m137.4m140.7m147.7m157.4m159.7m163.4m163.7m164.9m200.7m201.9m212.8m223.1m236.8m249.0m258.0m259.8m271.3m288.5m297.1m308.9m324.7m
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

78.3m(69.8m)3.1m7.0m(17.5m)65.3m35.4m81.3m12.5m65.2m

Depreciation and Amortization

36.7m36.2m51.9m63.1m82.3m83.8m125.4m141.7m149.9m135.6m

Inventories

(18.7m)(17.2m)(11.0m)(21.0m)(21.3m)(26.0m)(22.6m)(35.3m)(38.6m)(54.9m)

Accounts Payable

11.6m(3.4m)2.9m21.8m22.3m7.7m11.9m(5.6m)20.5m(3.3m)
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

7.8m16.4m2.4m7.7m(59.8m)673.0k3.5m5.9m851.0k(5.6m)1.9m(18.3m)(22.4m)(24.2m)31.4m41.4m54.2m(9.3m)26.0m29.5m12.3m24.6m57.7m(27.1m)(15.6m)322.0k9.4m24.3m35.4m5.3m

Depreciation and Amortization

17.1m27.4m7.8m15.9m24.8m12.1m25.3m38.2m14.6m30.3m46.3m15.4m31.0m46.5m20.4m41.4m62.3m26.3m57.3m90.7m34.9m69.6m104.6m37.0m74.1m111.4m39.3m78.1m101.2m35.0m

Inventories

(4.3m)(10.0m)(6.7m)(12.1m)(19.9m)(3.5m)(11.0m)14.2m(4.1m)(13.7m)(16.7m)(11.7m)(20.9m)(27.2m)(11.4m)(15.2m)(19.8m)9.4m12.0m(22.4m)(13.6m)(29.0m)(36.2m)(12.1m)(19.6m)(33.5m)(19.3m)(31.9m)(45.6m)(21.1m)

Accounts Payable

4.6m6.3m4.0m(2.3m)504.0k7.8m7.1m4.5m10.4m8.8m10.4m4.5m5.1m16.0m17.4m6.8m8.8m10.0m14.3m5.9m593.0k5.0m(5.9m)1.6m9.0m21.7m(2.5m)9.3m7.4m(5.3m)
show all
USDQ2, 2010

Financial Leverage

2.1 x
Show all financial metrics

NuVasive Acquisitions / Subsidiaries

Company NameDateDeal Size
SafePassageDecember 12, 2017
Biotronic NeuroNetworkJune 06, 2016$98 m
Ellipse TechnologiesJanuary 05, 2016$410 m

NuVasive Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

Learn more about about our premium products
SecurityScorecard logo

NuVasive Online and Social Media Presence

NuVasive's Trends

Embed Graph

NuVasive News and Updates

June 18, 2020

NuVasive Expands Complex Spine Portfolio with Global Launch of Reline 3D for Pediatric Deformity

SAN DIEGO, June 18, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the expansion of its complex spine portfolio with the...
June 05, 2020

DLA Piper advises NuVasive in its US$400 million convertible senior notes offering

NEW YORK, June 5, 2020 /PRNewswire/ -- DLA Piper represented advised NuVasive, Inc. (NASDAQ: NUVA), a San Diego-based medical device company that creates and distributes products for surgical treatment of spine disorders, in its offering of US$400 million aggregate principal amount of...
May 28, 2020

NuVasive, Inc. Announces Pricing Of Offering Of $400 Million Of 1.00% Convertible Senior Notes Due 2023

SAN DIEGO, May 28, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today the pricing of its offering (the "Offering") of $400.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2023 (the "Convertible Notes") in a private placement to qualified...
February 27, 2020

NuVasive, Inc. Announces Pricing Of Offering Of $450 Million Of 0.375% Convertible Senior Notes Due 2025

SAN DIEGO, Feb. 26, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today the pricing of its offering of $450,000,000 aggregate principal amount of 0.375% Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement to qualified institutional buyers...
January 15, 2020

Focus on Stem Cell and Primary Cell Culture Medium Market Changing the Way of Business in Upcoming Year with Profiling Key Merck, Irvinesci, Promocell, NuVasive

The Stem Cell and Primary Cell Culture Medium market was valued at xx Million US$ in 2020 and is projected to reach xx Million US$ by 2026, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the ma…
January 13, 2020

NuVasive Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue Results

SAN DIEGO, Jan. 13, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced preliminary unaudited revenue results for the fourth...
Show more

NuVasive Blogs

May 12, 2020

NuVasive to Participate in UBS Virtual Global Healthcare Conference

SAN DIEGO , May 12, 2020 /PRNewswire/ --  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will present at the UBS Virtual Global Healthcare
May 06, 2020

NuVasive Announces First Quarter 2020 Financial Results

SAN DIEGO , May 6, 2020 /PRNewswire/ --  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2020 .
May 05, 2020

NuVasive Expands Advanced Materials Science™ Implant Portfolio to Additional Thoracolumbar Procedures

SAN DIEGO , May 5, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the expansion of its Advanced Materials Science™ (AMS) implant
May 04, 2020

NuVasive to Participate in BofA Securities 2020 Healthcare Conference

SAN DIEGO , May 4, 2020 /PRNewswire/ --  NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will present at the virtual BofA Securities 2020
March 26, 2020

NuVasive celebrates Women’s History month

March is Women’s History Month—a month dedicated to celebrating the accomplishments and contributions women have made in our history and culture. At NuVasive, we are proud to work among, and celebrate women with diverse backgrounds and talents. We are prioritizing our efforts, through programs like …
March 10, 2020

Randomized Controlled Trial Results Published in 'Spine' Demonstrate Efficacy of NuVasive Attrax® Putty in Posterolateral Lumbar Fusion

Randomized Controlled Trial Results Published in 'Spine' Demonstrate Efficacy of NuVasive Attrax® Putty in Posterolateral Lumbar Fusion Content Import Tue, 03/10/2020 - 08:33 Randomized Controlled Trial Results Published in 'Spine' Demonstrate Efficacy of NuVasive Attrax® Putty in Posterol…
Show more

 NuVasive Frequently Asked Questions

  • When was NuVasive founded?

    NuVasive was founded in 1997.

  • Who are NuVasive key executives?

    NuVasive's key executives are Matt Harbaugh, Dale Wolf and Lucas Vitale.

  • How many employees does NuVasive have?

    NuVasive has 2,800 employees.

  • What is NuVasive revenue?

    Latest NuVasive annual revenue is $1.2 b.

  • What is NuVasive revenue per employee?

    Latest NuVasive revenue per employee is $417.2 k.

  • Who are NuVasive competitors?

    Competitors of NuVasive include Stryker, Integra LifeSciences and Cook Medical.

  • Where is NuVasive headquarters?

    NuVasive headquarters is located at 7475 Lusk Blvd, San Diego.

  • Where are NuVasive offices?

    NuVasive has offices in San Diego, Aliso Viejo, Columbia, Fairborn and in 14 other locations.

  • How many offices does NuVasive have?

    NuVasive has 18 offices.